Robert Franklin, MD
Addiction Medicine · Sacramento, CANPI 1164533329
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 41.7% of the total. Reporting peaked in 2024 at $623 and has fallen 91.3% since, to $54 in 2025.
Across 94 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$766
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$275
- Otsuka America Pharmaceutical, Inc.$171
- Alkermes, Inc.$169
- Lundbeck LLC$106
- Neurocrine Biosciences, Inc.$104
- plus $246 from 5 others
What the payments were for
- Food & beverage$1,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $766 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $275 |
| Otsuka America Pharmaceutical, Inc. | 7 | $171 |
| Alkermes, Inc. | 8 | $169 |
| Lundbeck LLC | 6 | $106 |
| Neurocrine Biosciences, Inc. | 4 | $104 |
| Indivior Inc. | 4 | $81 |
| AbbVie | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$255
- INVEGA TRINZA$126
How this compares
$1,836 in reported general payments places this provider in the 85th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 26 | $4,614 |
| Aripiprazole | 18 | $2,719 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $1,109 |
| Bupropion XlBupropion Hcl | 74 | $912 |
| Olanzapine OdtOlanzapine | 16 | $870 |
| Olanzapine | 16 | $361 |
| Quetiapine Fumarate | 14 | $84 |
| Trazodone Hcl | 13 | $54 |
| Prazosin Hcl | 15 | $47 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Sacramento
- Neal MehraSacramento$4K
- Jagdeep KaurSacramento$1K
- Angella BarrSacramento$625
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.